Henlius, Intas

Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY® in European markets as First-Line Treatment for adult patients with Extensive-Stage Small Cell Lung Cancer

Published on 08/07/2025 at 18:05 | prnewswire.co.uk

Accord Healthcare Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom China India

View original content:https://www.prnewswire.co.uk/news-releases/henlius-and-intas-receive-positive-chmp-opinion-for-hetronifly-approved-as-hansizhuang-in-china-in-european-markets-as-first-line-treatment-for-adult-patients-with-extensive-stage-small-cell-lung-cancer-302254345.html

en | boerse | 67963869 |